Treatment of systemic sclerosis

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Systemic sclerosis (SSc) is a complex autoimmune disease with highly variable clinical presentations.
• Distinguishing between limited and diffuse SSc is crucial for predicting disease course and guiding management.
• Patient management necessitates a personalized approach due to the heterogeneity of SSc manifestations.

Purpose of the Study:

• To highlight the differences in natural history between limited and diffuse systemic sclerosis.
• To emphasize the importance of individualized treatment strategies based on SSc subset and organ involvement.
• To review current and emerging therapeutic advances for systemic sclerosis.

Main Methods:

• Review of clinical manifestations and natural history of limited and diffuse SSc subtypes.
• Analysis of current organ-specific treatment strategies for SSc complications.
• Summary of findings from controlled clinical trials investigating various therapeutic agents for SSc.

Main Results:

• Limited SSc typically presents with prolonged Raynaud's phenomenon and puffy fingers before skin thickening, while diffuse SSc has an acute onset with hand swelling.
• Organ-specific therapies (e.g., calcium channel blockers, proton pump inhibitors, ACE inhibitors) have significantly reduced SSc-related morbidity and mortality.
• Controlled trials of agents like penicillamine, methotrexate, and interferons have shown variable outcomes, and a definitive remittive therapy is still under investigation.

Conclusions:

• Understanding the distinct natural histories of limited and diffuse SSc allows for more effective proactive and reactive patient management.
• Current therapeutic advances focus on managing specific organ system involvement, leading to improved patient quality of life.
• Ongoing research aims to identify effective disease-modifying or remittive therapies for systemic sclerosis.